Research has now also established that the cardiovascular and kidney advantages seen in individuals with type 2 diabetes mellitus (T2DM) who are treated with SGLT2 inhibitors are applicable to those without T2DM as well [35]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.